Ethical Understanding in AI Governance for Healthcare

By Sumona Bose

January 18, 2024

Introduction

The rapid advancement of artificial intelligence (AI) technologies in healthcare has brought about numerous benefits and opportunities. However, the lack of internationally recognized governance mechanisms for AI in healthcare poses challenges in terms of safety, ethics, and market competition. This article explores the need for ethical understanding in AI governance and its impact on AI, digital health, and governance.

Ensuring Safety and Addressing Ethical Concerns

The implementation of AI systems in frontline healthcare settings can raise safety concerns due to their unpredictable performance in diverse environments and unknown human-computer interactions. The lack of clarity around accountability and liability, as well as the insufficient education and preparedness among healthcare professionals, further exacerbate these concerns. To ensure the safety and ethical use of AI in healthcare, appropriate governance mechanisms such as policies, ethical standards, evaluation, and regulation need to be established.

Promoting Market Competition

The absence of international consensus on AI governance hampers market competition and innovation. An open and competitive ecosystem of innovators is crucial for healthcare systems worldwide to derive optimal benefits from AI investments. However, the lack of unified standards and diverse regulatory requirements force companies to develop different AI technologies for different markets. This lack of uniformity makes it challenging for start-ups and small businesses to compete with larger incumbents, potentially leading to their acquisition. Addressing this issue is essential to prevent provider monopolies and vendor lock-in, which have hindered technology transformation programs in the past.

Ensuring High Standards of Safety, Efficacy, and Ethics:

Healthcare is a safety-critical area where poorly designed AI-driven tools can cause harm to healthcare practitioners and patients. Therefore, it is crucial for all nations to strive for the same high standards of safety, efficacy, and ethics in health AI products, tools, and systems. Calls for greater international policy cooperation from academia, policymakers, and industries are growing louder. International coordination can help reduce gaps in guidance and regulation, make quality and safety standards visible and clear, and provide a common reference for developers and users.

International Initiatives for AI Governance

Recognizing the need for international cooperation in AI governance, several initiatives have been established. The World Health Organization (WHO) and the International Telecommunication Union (ITU) formed the Focus Group on Artificial Intelligence for Health (FG-AI4H) in 2018. This group is working on developing a benchmarking process and a standardized evaluation framework for health AI models. Understanding AI governance contributes to building a framework which can normalize the use of AI in healthcare.

Conclusion

The lack of internationally recognized governance mechanisms for AI in healthcare poses significant challenges in terms of safety, ethics, and market competition. To ensure the ethical use of AI in healthcare, it is crucial to establish appropriate governance mechanisms such as policies, ethical standards, evaluation, and regulation.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.